Back To Schedule
Monday, June 15 • 3:30pm - 4:30pm
#132 SL: Benchmarking and Identifying Opportunities to Improve Intentional Dose Non-Adherence in Clinical Trials

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Forum
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-20-561-L04-P; CME 1.00; IACET 1.00; RN 1.00

The results of a groundbreaking study quantifying intentional dose non-adherence are presented followed by a discussion among a panel of clinical and regulatory professionals on the implications of the findings.

Learning Objectives

Quantify intentional dose non-adherence rates in clinical trials; Identify factors associated with, and predictive of intentional non-adherence; Discuss policies and solutions to address and reduce intentional non-adherence.


Kenneth A. Getz, MBA


Quantifying the Magnitude of Intentional Dose Non Adherence
Kenneth A. Getz, MBA

Accounting For and Managing Dose Non-Adherence in Clinical Trials
Marlen Rattiner, MA

avatar for Kenneth Getz

Kenneth Getz

Executive Director/Professor, Tufts CSDD; Founder/Board Chair, CISCRP, Tufts University School of Medicine, United States
Ken Getz is a Professor and the Executive Director of the Center for the Study of Drug Development, Tufts University School of Medicine, where he conducts grant-funded studies on pharmaceutical R&D management and execution; protocol design optimization; CRO and investigative site... Read More →

Marlen Rattiner

Vice President, Product Management, AiCure

Monday June 15, 2020 3:30pm - 4:30pm EDT
TBD Virtual Event Horsham, PA 19044
  08: R-D Quality-Compliance, Forum